NCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
Clinical Trials
10 trialsNCT06490913 2024-07-08
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06321081 2024-03-20
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Beijing Hospital
Phase 2 Recruiting
NCT06226857 2024-01-29
CRC01
City Clinical Oncology Hospital No 1
Phase 3 Recruiting
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT00640081 2021-09-22
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
Medical Research Council
Phase 2 Completed
NCT00557102 2012-12-11
ERBIFORT
National Cancer Institute, France
Phase 2 Completed
NCT01301248 2011-05-17
Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck
Theagenio Cancer Hospital
Phase 2 Unknown
NCT00784667 2010-11-30
Dux
Austin Health
Phase 2 Unknown
NCT00506844 2007-07-25
ERBIRIX
National Cancer Center, Korea
Phase 2 Unknown